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Abstract
Background: Sarcoidosis is a poorly understood chronic inflammatory condition. Infiltration of affected organs by
lymphocytes is characteristic of sarcoidosis, however previous reports suggest that circulating lymphocyte counts are low in
some patients with the disease. The goal of this study was to evaluate lymphocyte subsets in peripheral blood in a cohort of
sarcoidosis patients to determine the prevalence, severity, and clinical features associated with lymphopenia in major
lymphocyte subsets.
Methodology/Principal Findings: Lymphocyte subsets in 28 sarcoid patients were analyzed using flow cytometry to
determine the percentage of CD4, CD8, and CD19 positive cells. Greater than 50% of patients had abnormally low CD4, CD8,
or CD19 counts (p,4610
210). Lymphopenia was profound in some cases, and five of the patients had absolute CD4 counts
below 200. CD4, CD8, and CD19 lymphocyte subset counts were significantly correlated (Spearman’s rho 0.57, p=0.0017),
and 10 patients had low counts in all three subsets. Patients with severe organ system involvement including neurologic,
cardiac, ocular, and advanced pulmonary disease had lower lymphocyte subset counts as a group than those patients with
less severe manifestations (CD4 p=0.0043, CD8 p=0.026, CD19 p=0.033). No significant relationships were observed
between various medical therapies and lymphocyte counts, and lymphopenia was present in patients who were not
receiving any medical therapy.
Conclusions/Significance: Significant lymphopenia involving CD4, CD8, and CD19 positive cells was common in sarcoidosis
patients and correlated with disease severity. Our findings suggest that lymphopenia relates more to disease pathology
than medical treatment.
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Introduction
Sarcoidosis is a systemic inflammatory disease characterized by
noncaseating granulomas which consist of CD4
+ T-cells and
macrophages surrounded by CD8
+ T - c e l l s[ 1 ] .T h i si n f l a m m a t i o n
can affect any number of organs,including the lung, liver, heart, skin,
and nervous system. The etiology of sarcoidosis is unknown, but likely
involves genetic factors, which interact with environmental exposures
to result in disease susceptibility [2]. The immune dysregulation in
sarcoidosis is classically manifested by hypergammaglobulinemia
and paradoxical cutaneous anergy to particular antigens such as
tuberculin protein [3]. This paradox of anergy co-existing with an
inflammatory condition remains poorly understood.
Lymphopenia occurs in over 50% of sarcoidosis patients and is
associated with chronic disease [4,5,6]. While early studies have
suggested that sarcoidosis-associated lymphopenia is due to T-cell
depletion [7], few studies have focused on the various peripheral
blood lymphocyte subsets in sarcoidosis. Miyara and colleagues
PLoS ONE | www.plosone.org 1 February 2010 | Volume 5 | Issue 2 | e9088investigated the presence and function of regulatory T cells in the
lung and blood of patients with sarcoidosis. It was demonstrated
that CD4
+CD25
brightFoxP3
+ cells accumulated in the periphery of
sarcoid granulomas, in BAL washings, and in peripheral blood of
patients with active disease. These cells effectively suppressed the
proliferation of effector cells but not their production of TNF. This
may explain the paradoxical state of T cell anergy in these patients
that is associated with active local inflammation. However, to our
knowledge, detailed examination of the various lymphocyte
subsets in the peripheral blood in sarcoidosis patients has not
been described. Thus, the goal of this study was to evaluate
lymphocyte subsets in peripheral blood in a cohort of sarcoidosis
patients followed at the University of Chicago Rheumatology
Clinic to determine the prevalence, severity, and clinical features
associated with lymphopenia in major lymphocyte subsets.
Materials and Methods
Weperformedaretrospective reviewofthe laboratoryrecordsfor
lymphocyte subset testing in sarcoidosis patients at the University of
Chicago Hospital between November 2006 and January 2008. Our
analysis was limited to individuals who received full testing by flow
cytometry and included the following cell counts: Absolute CD4
(515–1642 cells/mL), CD8(212–887 cells/mL) and CD19 (103–581
cells/mL). The medical records of patients and controls were
reviewed according to the study approved by the University of
Chicago Institutional Review Board. Because this was a retrospec-
tive chart review, patient consent was waived by the Institutional
Review Board as the study approved by the Institutional Review
Board required no therapeutic intervention. Twenty-eight patients
were identified. Inclusion criteria were patients with biopsy-proven
sarcoidosis who attended the University of Chicago Sarcoidosis
Center for new or return appointments and had full lymphocyte
subset data available.
Clinical data were obtained by the primary study physician
(NJS) and abstracted to include clinical manifestations related to
sarcoidosis, demographics, and medical therapy. Lymphocyte
subset data in the sarcoidosis cohort were compared to 100 healthy
individuals who were tested by the clinical laboratory for assay
standardization. Results were also compared between groups of
patients defined by disease manifestations or medical treatment.
Severe organ system involvement was defined as chronic
sarcoidosis with at least one of the following disease manifestations:
neurologic, cardiac, ocular, or advanced pulmonary disease
defined as forced vital capacity (FVC),40% of predicted. Patients
with severe sarcoidosis typically require corticosteroid-sparing
agents secondary to corticosteroid failure.
Flow Cytometry
CD4, CD8, and CD19 cells were counted in whole blood using
flow cytometry techniques at the University of Chicago Clinical
Laboratory following standard protocols with fluorescently labeled
antibodies. The proportion of cells positive for CD4, CD8, and
CD19 was multiplied by the total number of lymphocytes, and cell
counts were reported as number of cells per microliter (cells/mL).
Normal ranges for CD4, CD8, and CD19 cell populations were
derived from the healthy donor cohort used to standardize the
assay. Low count was defined as results below the lower level of
normal for CD4 (515–1642 cells/mL), CD8 (212–887 cells/mL)
and CD19 (103–581 cells/mL).
Statistical Analysis
Fisher’s exact test was used to compare categorical data,
and quantitative comparisons were performed using an unpaired
t-test or Mann-Whitney non-parametric t-test as appropriate
depending upon whether the data were normally distributed as
assessed by the D’Agostino and Pearson omnibus normality test.
P-values shown are all two-sided, and uncorrected for multiple
comparisons.
Results
Patient Characteristics
In this cohort of 28 sarcoidosis patients, 18 were African-
American, and ten were European-American. The mean age was
51.6 years, with a wide spectrum of organ system involvement
(Table 1). Seven patients (25%) had cardiac and 7 had skin
involvement, 4 patients (14%) had clinically significant lung
involvement, 4 (14%) had neurologic involvement, and 6 patients
(21%) had liver involvement. A total of 24/28 patients in this
cohort (86%) required therapy.
Significant CD4, CD8, and CD19 Lymphopenia Was
Present in Sarcoidosis Patients
The majority of sarcoidosis patients exhibited reduced lympho-
cyte subset counts, including CD4 (57%), CD8 (54%), and CD19
cell counts (54%) as compared to healthy controls (Figure 1A,
p,4610
210). Only eight patients (29%) demonstrated values
within the normal range for all three lymphocyte subsets.
Lymphopenia was profound in some cases, and five of the patients
had absolute CD4 counts below 200. There were no significant
differences by gender or ethnicity (European vs. African-American
ancestry) in any of the lymphocyte subset counts. CD4, CD8, and
CD19 lymphocyte counts were significantly correlated (Spear-
man’s rho 0.57, p=0.0017, Figure 1B), and 10 patients (36%)
exhibited reduced lymphocyte counts in all three subsets.
Lymphopenia in Sarcoidosis Patients Is Not Related to
Medical Therapy but Instead to Severity of Disease
Reductions in lymphocyte subset counts were not significantly
different in patients who were taking disease-modifying anti-
rheumatic drugs (DMARDs, including methotrexate, azathio-
prine, leflunomide and mycophenolate mofetil) (n=14), predni-
sone (n=18) or tumor necrosis factor alpha (TNF-a) inhibitors
(n=6) (p.0.5, data not shown). Four patients had not been taking
any medical therapy, and three of these patients had abnormally
low lymphocyte counts. Patients with severe organ system
involvement as defined in the Methods had lower lymphocyte
Table 1. Demographic and Clinical Information for the
Cohort.
Total # of patients 28
# of African-American 18
# of European-American 10
Average age of patient (yrs) 51.6
Number of pt with severe disease No. (%) 18 (64%)
Heart Involvement No. (%) 7 (25%)
Skin Involvement No. (%) 7 (25%)
Lung Involvement No. (%) 4 (14%)
Liver Involvement No. (%) 6 (21%)
Neurologic Involvement No. (%) 4 (14%)
Number of patients requiring therapy No. (%) 26 (86%)
doi:10.1371/journal.pone.0009088.t001
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these disease manifestations (CD4 p=0.0043, CD8 p=0.026,
CD19 p=0.033, Figure 2).
Discussion
This study provides the first report of frequent and severe
CD4, CD8, and CD19 lymphopenia in sarcoidosis patients to
our knowledge. All lymphocyte subsets were highly correlated
with each other, suggesting that many patients have severe overall
T- and B-cell lymphopenia in peripheral blood. Lymphopenia
was frequently present in patients who were not receiving any
medical therapy, and while immunosuppressive therapies may
reduce lymphocyte numbers in the peripheral blood [8], we
found that there were no significant relationships between specific
medical therapies and lymphocyte counts. In contrast, severe
organ system involvement was associated with lower lymphocyte
subset counts, suggesting that lymphopenia may relate more to
disease pathology than medical therapy. This finding could
suggest that lymphocytes are depleted in peripheral blood due to
increased infiltration of target organs. In one study of pulmonary
sarcoidosis patients undergoing bronchoalveolar lavage (BAL),
there was a was a significant relationship between an increase
in the number of CD4 positive T cells in the BAL fluid and
a decrease in the absolute number of CD4 positive T cells in
the peripheral blood [9]. Alternatively, lymphopenia could
represent either suppression of lymphogenesis due to cytokines or
other influences, or increased peripheral destruction due to
activation-driven cell death or other mechanisms. Longitudinal
follow up studies would be of high interest to determine
whether lymphopenia is corrected with therapy, as other disease
manifestations are effectively treated. Such results would
further strengthen the hypothesis that lymphopenia underlies
disease pathology rather than being a result of generalized
immunosuppression.
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Figure 1. Absolute counts and correlation between CD4, CD8,
and CD19 lymphocytes in sarcoidosis. A) Peripheral blood
lymphocyte measurements show that 16 patients (57%) had lower
than normal CD4 counts, 15 patients (54%) had lower than normal CD8
counts, and 15 patients (54%) had lower than normal CD19 counts. The
box indicates the normal range for cell counts (95% of normal control
subjects fell within this normal range) (p,4610
210). B) Correlation
between lymphocyte counts in sarcoidosis patients. CD4:CD8 correla-
tion shown in purple, and CD4:CD19 shown in blue, with Spearman’s
rho and p-value indicated for each correlation.
doi:10.1371/journal.pone.0009088.g001
Figure 2. Lymphocyte counts in patients with severe organ
system involvement vs. those without severe organ system
involvement. Severe organ system involvement is defined as outlined
in the methods.
doi:10.1371/journal.pone.0009088.g002
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